Biohaven (BHVN) director awarded 68,693 options vesting in 2027

Q: What insider transaction did Biohaven (BHVN) report for Irina Antonijevic?

Biohaven reported that director Irina Antonijevic received a grant of stock options for 68,693 common shares . The options carry an exercise price of 9.61 per share , vest in 2027, and represent compensation rather than an open-market share purchase or sale.

Q: When do Irina Antonijevic’s Biohaven (BHVN) stock options vest?

The options granted to Irina Antonijevic will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders . Vesting is conditioned on her continuous service with the company through the applicable vesting date.

Q: What is the exercise price and term of the new Biohaven (BHVN) stock options?

The granted stock options have an exercise price of 9.61 per share and an expiration date of April 28, 2036 . This gives the director roughly a ten-year period after grant during which the options can be exercised, subject to vesting and continued service conditions.

Q: How many Biohaven (BHVN) options does Irina Antonijevic hold after this grant?

Following this transaction, Irina Antonijevic holds 68,693 stock options directly, each linked to one common share. This entire amount reflects the newly granted options reported, and there are no additional derivative holdings disclosed in this particular filing excerpt.

Q: Is the Biohaven (BHVN) Form 4 transaction a market buy or sell?

The Form 4 shows a grant/award acquisition of stock options, coded as an “A” transaction , not an open-market buy or sell. It represents equity-based compensation, with no indication of Biohaven shares being purchased or sold in the public market.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Biohaven Ltd. director Irina Antonijevic received a grant of stock options covering 68,693 common shares, with an exercise price of 9.61 per share. These options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, subject to her continuous service, and expire on April 28, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Antonijevic Irina

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	68,693	$0.00	--

Holdings After Transaction: Stock Options (Right to buy) — 68,693 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 68,693 options Exercise price: 9.61 per share Total options after grant: 68,693 options +2 more

5 metrics

Options granted 68,693 options Stock options on common shares granted to director

Exercise price 9.61 per share Exercise price for the granted stock options

Total options after grant 68,693 options Total derivative holdings following transaction

Vesting date Earlier of April 28, 2027 or 2027 meeting Full vesting date, subject to continuous service

Expiration date April 28, 2036 Option term end date

Key Terms

Stock Options (Right to buy), exercise price, expiration date, Annual Meeting of Shareholders, +1 more

5 terms

Stock Options (Right to buy) financial

"security_title: "Stock Options (Right to buy)""

exercise price financial

"conversion_or_exercise_price: "9.6100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-04-28T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Annual Meeting of Shareholders financial

"the date of the 2027 Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

04/30/2026 - 07:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Antonijevic Irina

(Last)

(First)

(Middle)

C/O BIOHAVEN LTD.

215 CHURCH STREET

(Street)

NEW HAVEN

CONNECTICUT

06510

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to buy)	$9.61	04/28/2026		A		68,693		⁽¹⁾	04/28/2036	Common Shares	68,693	$0	68,693	D

Explanation of Responses:

1. The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Remarks:

	/s/ George Clark, Attorney-in-Fact	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Biohaven (BHVN) report for Irina Antonijevic?

Biohaven reported that director Irina Antonijevic received a grant of stock options for 68,693 common shares. The options carry an exercise price of 9.61 per share, vest in 2027, and represent compensation rather than an open-market share purchase or sale.

When do Irina Antonijevic’s Biohaven (BHVN) stock options vest?

The options granted to Irina Antonijevic will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders. Vesting is conditioned on her continuous service with the company through the applicable vesting date.

What is the exercise price and term of the new Biohaven (BHVN) stock options?

The granted stock options have an exercise price of 9.61 per share and an expiration date of April 28, 2036. This gives the director roughly a ten-year period after grant during which the options can be exercised, subject to vesting and continued service conditions.

How many Biohaven (BHVN) options does Irina Antonijevic hold after this grant?

Following this transaction, Irina Antonijevic holds 68,693 stock options directly, each linked to one common share. This entire amount reflects the newly granted options reported, and there are no additional derivative holdings disclosed in this particular filing excerpt.

Is the Biohaven (BHVN) Form 4 transaction a market buy or sell?

The Form 4 shows a grant/award acquisition of stock options, coded as an “A” transaction, not an open-market buy or sell. It represents equity-based compensation, with no indication of Biohaven shares being purchased or sold in the public market.